The FDA Approval of a Monoclonal Antibody for Treating Alzheimer's Disease

Laconimab is a monoclonal antibody for treating Alzheimer's disease that targets beta amyloid. The FDA approved Laconimab through the accelerated approval program on the basis of a surrogate marker changes inbeta amyloid on brain imaging. There are some concerning safety signals as these therapies seem to be associated with an increased risk of brain hemorrhage and micro edema, which resolves when the therapy is discontinued.